Streetbeat News

Equity Actions

PETV

PetVivo Holdings, Inc. has announced the appointment of Garry Lowenthal as its new Chief Financial Officer. Lowenthal brings over 25 years of experience in senior operations and finance management roles across both private and public companies. His background includes significant expertise in equity capital raising transactions, financial and corporate management, and serving in advisory roles for various organizations. PetVivo, an emerging biomedical device company focused on companion animals and animal athletes, expects Lowenthal's expertise to further its mission and enhance shareholder value.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:07 pm

HZO

MarineMax, a recreational boat and yacht retailer, has announced a new stock repurchase program allowing the company to buy back up to $100 million of its own shares. This move is aimed at returning value to shareholders and reflects the company's confidence in its financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:03 pm

BIOR

Biora Therapeutics, Inc. (NASDAQ:BIOR) has announced a series of financial transactions aimed at reducing its net debt and raising new capital. The company has exchanged convertible notes for new capital and senior secured notes, bringing in $2.8 million. Additionally, Biora has monetized its investment in Enumera Molecular, Inc., resulting in $3 million of nondilutive funding. These transactions are part of Biora's efforts to optimize its capital structure and fund its therapeutic programs. The company has reduced its debt by over $80 million since September 2023 through note exchange transactions, with institutional investors contributing $19.8 million of new capital.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:02 pm

ARCT

Arcturus Therapeutics (NASDAQ:ARCT) has seen a variety of analyst ratings over the past three months, with a recent positive shift in sentiment. Four analysts have provided ratings, with the latest 12-month price targets showing an average of $63.25, up 14.31% from the previous $55.33. The company's financial performance has been strong, with significant revenue growth and above-average financial metrics compared to the industry. Arcturus focuses on RNA medicines for rare diseases, with a notable pipeline including LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 12:01 pm

CGC

Canopy Growth Corporation (CGC) announced a special resolution for shareholders to vote on creating an unlimited number of new non-voting, non-participating exchangeable shares. This amendment also includes a conversion feature allowing common shares to be converted into exchangeable shares and vice versa. The vote is scheduled for April 12, 2024. If approved, this will enable shareholders to convert their shares post the effective time of the amendment. Notices of Conversion will be available on the company's website and filed with the SEC and Canadian regulators.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:59 am

IVCB

Investcorp Europe Acquisition Corp I (IVCB) has amended its Business Combination Agreement (BCA) following the divestiture of OpSec Security, which is to be acquired by Crane NXT for $270 million. The amendment involves Zacco becoming a stand-alone business. The Board of Directors of Investcorp Europe is currently evaluating the amended BCA to consider a merger with Zacco and intends to seek a deadline extension to complete the initial business combination.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:42 am

LXEO

Lexeo Therapeutics has successfully completed an oversubscribed $95M equity financing round, selling 6.278 million shares at $15.13 each to institutional and healthcare accredited investors in a private placement.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:39 am

LXRX

Lexicon Pharmaceuticals' shares surged after the company announced plans to resubmit its Sotagliflozin NDA for Type 1 diabetes based on FDA feedback. Furthermore, Lexicon revealed a securities purchase agreement anticipated to generate approximately $250 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:22 am

LXRX

Lexicon Pharmaceuticals, Inc. has announced an oversubscribed $250 million private placement of equity securities. This significant capital raise indicates strong investor interest and confidence in Lexicon's future prospects.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:08 am

EOLS

Evolus announced the pricing of a $50M offering of common stock, with an option for underwriters to purchase up to an additional 533,100 shares. The offering is expected to close around March 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:03 am